Armata Pharmaceuticals, Inc. — Director's Dealing 2015

Mar 18, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AmpliPhi Biosciences Corp (APHB)
CIK: 0000921114
Period of Report: 2015-03-16

Reporting Person: KIRK RANDAL J (10% Owner)
Reporting Person: INTREXON CORP (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-03-16	Common Stock	P	13939392	$0.165	Acquired	37939392	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-03-16	Warrant to Purchase Common Stock	$0.215	P	3484848	Acquired	2020-03-16	Common Stock (3484848)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20000000	Indirect

Footnotes

F1: Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon Corporation. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon Corporation. Shares held by Intrexon Corporation may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F2: Randal J. Kirk controls NRM VII Holdings I, LLC ("NRM VII Holdings"). Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest
therein.

F3: The warrants will be exercisable beginning on the date the issuer effects a reverse stock split or increases the number of authorized shares of common stock, in either case in an amount sufficient to permit the exercise in full of these warrants.

F4: On March 16, 2015, in a private placement, Intrexon Corporation purchased 13,939,392 shares of common stock of the issuer and in connection therewith the issuer issued to Intrexon Corporation warrants to purchase 0.25 shares of common stock for each share of common stock purchased, or warrants to purchase 3,484,848 shares of common stock in the aggregate.